001-31668 |
22-2407475 |
(COMMISSION FILE NUMBER)
|
(I.R.S. EMPLOYER IDENTIFICATION NO.)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
None
|
None
|
None
|
Broker
| |||||
For
|
Withheld
|
Non-Votes
| |||
Eric Friedman
| 21,738,259 | 85,901 | 1,634,717 |
Proposal No. 2 - To ratify the appointment of the Company's independent auditors for the fiscal year ending June 30, 2023
For
|
Against
|
Abstain
| ||
23,403,076 | 25,801 | 30,000 |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Exhibit |
Description | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
INTEGRATED BIOPHARMA, INC. | |
Date: November 28, 2022
|
By: /s/ Dina L Masi |
Dina L Masi
| |
Chief Financial Officer
|
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Integrated BioPharma Inc. published this content on 28 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 November 2022 19:32:50 UTC.